Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

NM404 · I124, CLR-1401

Radiopharmaceutical · developed by Cellectar Biosciences

Phase 1 Most advanced trial (none active)
CLRB Developer
1 Registered trials

What is NM404?

NM404 is an agent also known as I124 or CLR-1401, studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
I124, CLR-1401
Drug type
Radiopharmaceutical
Therapy area
Oncology
Developer
Cellectar Biosciences, Inc. (CLRB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
7EC9WBC6KF

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00582283 Phase 1 Non Small Cell Lung Cancer Completed CLRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Small Cell Lung Cancer

More from Cellectar Biosciences

Cyclophosphamate Phase 3 Iodine I 124 Iopofosine Phase 2 Iodine I 125 Iopofosine Phase 1 Iodine I 131 Iopofosine Phase 3 NOV-002 Phase 3 NOV-205 Phase 2

Follow CLRB, the company behind NM404

See CLRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CLRB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.